204 related articles for article (PubMed ID: 21178496)
1. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans.
Jesus MD; Nicola AM; Chow SK; Lee IR; Nong S; Specht CA; Levitz SM; Casadevall A
Virulence; 2010; 1(6):500-8. PubMed ID: 21178496
[TBL] [Abstract][Full Text] [Related]
2. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
De Jesus M; Nicola AM; Rodrigues ML; Janbon G; Casadevall A
Eukaryot Cell; 2009 Jan; 8(1):96-103. PubMed ID: 18952901
[TBL] [Abstract][Full Text] [Related]
3. An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan.
van de Moer A; Salhi SL; Cherniak R; Pau B; Garrigues ML; Bastide JM
Res Immunol; 1990 Jan; 141(1):33-42. PubMed ID: 2189167
[TBL] [Abstract][Full Text] [Related]
4. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Todaro-Luck F; White EH; Reiss E; Cherniak R
Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
[TBL] [Abstract][Full Text] [Related]
5. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
Villena SN; Pinheiro RO; Pinheiro CS; Nunes MP; Takiya CM; DosReis GA; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
Cell Microbiol; 2008 Jun; 10(6):1274-85. PubMed ID: 18284419
[TBL] [Abstract][Full Text] [Related]
6. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
7. Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans.
Grijpstra J; Gerwig GJ; Wösten H; Kamerling JP; de Cock H
Eukaryot Cell; 2009 Aug; 8(8):1165-73. PubMed ID: 19542308
[TBL] [Abstract][Full Text] [Related]
8. Characterization of protein and mannan polysaccharide antigens of yeasts, moulds, and actinomycetes.
Reiss E; Huppert M; Cherniak R
Curr Top Med Mycol; 1985; 1():172-207. PubMed ID: 3916766
[TBL] [Abstract][Full Text] [Related]
9. Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable.
De Jesus M; Chow SK; Cordero RJ; Frases S; Casadevall A
Eukaryot Cell; 2010 Jul; 9(7):1018-28. PubMed ID: 20061411
[TBL] [Abstract][Full Text] [Related]
10. Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells.
Chaka W; Verheul AF; Vaishnav VV; Cherniak R; Scharringa J; Verhoef J; Snippe H; Hoepelman IM
Infect Immun; 1997 Jan; 65(1):272-8. PubMed ID: 8975923
[TBL] [Abstract][Full Text] [Related]
11. Mannoprotein MP84 mediates the adhesion of Cryptococcus neoformans to epithelial lung cells.
Teixeira PA; Penha LL; Mendonça-Previato L; Previato JO
Front Cell Infect Microbiol; 2014; 4():106. PubMed ID: 25191644
[TBL] [Abstract][Full Text] [Related]
12. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
13. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens.
Murphy JW; Mosley RL; Cherniak R; Reyes GH; Kozel TR; Reiss E
Infect Immun; 1988 Feb; 56(2):424-31. PubMed ID: 3123390
[TBL] [Abstract][Full Text] [Related]
14. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
15. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
16. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction.
McFadden DC; De Jesus M; Casadevall A
J Biol Chem; 2006 Jan; 281(4):1868-75. PubMed ID: 16278213
[TBL] [Abstract][Full Text] [Related]
17. A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan.
Albuquerque PC; Cordero RJ; Fonseca FL; Peres da Silva R; Ramos CL; Miranda KR; Casadevall A; Puccia R; Nosanchuk JD; Nimrichter L; Guimaraes AJ; Rodrigues ML
Fungal Genet Biol; 2012 Nov; 49(11):943-54. PubMed ID: 23010152
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.
Chow SK; Casadevall A
Vaccine; 2011 Feb; 29(10):1891-8. PubMed ID: 21238568
[TBL] [Abstract][Full Text] [Related]
19. A Predicted Mannoprotein Participates in
Reuwsaat JCV; Motta H; Garcia AWA; Vasconcelos CB; Marques BM; Oliveira NK; Rodrigues J; Ferrareze PAG; Frases S; Lopes W; Barcellos VA; Squizani ED; Horta JA; Schrank A; Rodrigues ML; Staats CC; Vainstein MH; Kmetzsch L
mSphere; 2018 Apr; 3(2):. PubMed ID: 29897877
[TBL] [Abstract][Full Text] [Related]
20. The capsule of the fungal pathogen Cryptococcus neoformans.
Zaragoza O; Rodrigues ML; De Jesus M; Frases S; Dadachova E; Casadevall A
Adv Appl Microbiol; 2009; 68():133-216. PubMed ID: 19426855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
